Advances in Multiple Sclerosis and Experimental Demyelinating Diseases

Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people in the United States. With their novel, multifaceted approach to basic science, the authors of this book offer help to clinicians and hope to patients.

• ISBN: 978-3-642-43783-0
• Editorial: Springer
• Encuadernacion: Rústica
• Fecha Publicación: 25/09/2014
• Nº Volúmenes: 1
• Idioma: Inglés